Spinal dopaminergic D1-and D2-like receptors have a sex-dependent effect in an experimental model of fibromyalgia

Luz-Cuellar, Yarim Elideth De la; Coffeen, Ulises; Mercado, Francisco García Gómez de; Granados‐Soto, Vinicio

doi:10.1016/j.ejphar.2023.175696

Cited by 3 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To avoid the potential interaction of estrogen signaling and the dopamine system [ 26 , 27 ], a total of 132 male SD rats were chosen for the experiments (specific-pathogen-free rats, provided by Chongqing Medical University). For primary neuron isolation, pregnant rats (Day 18) were chosen.…”

Section: Methodsmentioning

confidence: 99%

Dopamine D2 Receptor Activation Blocks GluA2/ROS Positive Feedback Loop to Alienate Chronic-Migraine-Associated Pain Sensitization

Zhang,

Lei

et al. 2024

Antioxidants

View full text Add to dashboard Cite

Chronic migraine is a disabling disorder without effective therapeutic medicine. AMPA receptors have been proven to be essential to pathological pain and headaches, but the related regulatory mechanisms in chronic migraine have not yet been explored. In this study, we found that the level of surface GluA2 was reduced in chronic migraine rats. Tat-GluR23Y (a GluA2 endocytosis inhibitor) reduced calcium inward flow and weakened synaptic structures, thus alleviating migraine-like pain sensitization. In addition, the inhibition of GluA2 endocytosis reduced the calcium influx and alleviated mitochondrial calcium overload and ROS generation in primary neurons. Furthermore, our results showed that ROS can induce allodynia and GluA2 endocytosis in rats, thus promoting migraine-like pain sensitization. In our previous study, the dopamine D2 receptor was identified as a potential target in the treatment of chronic migraine, and here we found that dopamine D2 receptor activation suppressed chronic-migraine-related pain sensitization through blocking the GluA2/ROS positive feedback loop in vivo and in vitro. Additionally, ligustrazine, a core component of ligusticum chuanxiong, was shown to target the dopamine D2 receptor, thereby alleviating ROS production and abnormal nociception in CM rats. This study provides valuable insight into the treatment of chronic migraine.

show abstract

Section: Methodsmentioning

confidence: 99%